Trial Profile
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 29 Jul 2021 Status changed from active, no longer recruiting to completed.
- 14 Dec 2019 Primary endpoint (Overall Response Rate) has not been met as per results presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 14 Dec 2019 Results presented at the 42nd Annual San Antonio Breast Cancer Symposium